Intensive topical steroid regimen for enhanced very early recovery after small incision lenticule extraction.
0.1% Fluorometholone
Defined daily dose (DDD)
Early phase
Myopia
Small incision lenticule extraction (SMILE)
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
23
11
2021
accepted:
09
07
2023
medline:
26
9
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
This study aims to investigate the topical steroid regimen after small incision lenticule extraction (SMILE) for its effect on very early restoration of visual quality. A total of 180 patients (360 eyes) who underwent SMILE were enrolled. These patients were randomly assigned to three groups, with 60 patients in each group. The only difference among these three groups was the administration of 0.1% fluorometholone (FML) eye drops within two hours after SMILE: no FML in group A, 0.1% FML once every hour in group B and 0.1% FML once every half hour in group C. The corrected distance visual acuity (CDVA), objective scattering index (OSI), modulation transfer function (MTF) cut-off, Strehl ratio (SR) and incidence of subjective symptoms were evaluated preoperatively, at 2, 4 and 24 h and one week after SMILE. The CDVA, MTF cut-off and SR values were significantly higher in group C, when compared to the other two groups, at 2 and 4 h after SMILE (p < 0.05). Furthermore, the OSI and incidence of subjective symptoms were significantly lower in group C, when compared to the other two groups, at 2 and 4 h after SMILE (p < 0.05). However, no significant differences in CDVA, MTF cut-off, SR, OSI and the incidence of subjective symptoms were detected among the three groups at 24 h and one week after SMILE (p > 0.05). The administration of 0.1% FML eye drops every half hour within two hours after SMILE accelerates the restoration of visual and optical quality, and reduces the incidence of subjective symptoms during the very early phase after surgery.
Identifiants
pubmed: 37561251
doi: 10.1007/s10792-023-02827-7
pii: 10.1007/s10792-023-02827-7
pmc: PMC10520117
doi:
Substances chimiques
Fluorometholone
SV0CSG527L
Ophthalmic Solutions
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4097-4103Informations de copyright
© 2023. The Author(s).
Références
J Ophthalmol. 2017;2017:5824534
pubmed: 28680704
BMC Ophthalmol. 2019 Apr 8;19(1):88
pubmed: 30961593
BMC Ophthalmol. 2021 Jan 19;21(1):46
pubmed: 33468076
J Refract Surg. 2014 Sep;30(9):590-6
pubmed: 25250415
J Ophthalmol. 2017;2017:5646390
pubmed: 28396803
Cornea. 2016 Feb;35(2):210-6
pubmed: 26684046
BMC Ophthalmol. 2019 Feb 8;19(1):21
pubmed: 30732575
BMC Ophthalmol. 2014 Oct 03;14:117
pubmed: 25280533
Am J Ophthalmol. 2014 Jan;157(1):128-134.e2
pubmed: 24112634
J Refract Surg. 2016 May 1;32(5):346-53
pubmed: 27163621
PLoS One. 2016 Jul 01;11(7):e0158176
pubmed: 27367803
Acta Ophthalmol. 2019 May;97(3):e373-e380
pubmed: 30632671
J Refract Surg. 2018 Jun 1;34(6):393-399
pubmed: 29889292
Int J Ophthalmol. 2021 Mar 18;14(3):423-429
pubmed: 33747820
Curr Eye Res. 2016 Oct;41(10):1316-1325
pubmed: 26863271
Br J Ophthalmol. 2014 Feb;98(2):263-9
pubmed: 24227802
Medicine (Baltimore). 2015 Feb;94(7):e551
pubmed: 25700323
J Refract Surg. 2016 Apr;32(4):256-65
pubmed: 27070233
Int Ophthalmol. 2021 Jul;41(7):2521-2531
pubmed: 33783676
Br J Ophthalmol. 2019 Apr;103(4):565-568
pubmed: 30061116
Invest Ophthalmol Vis Sci. 2011 Aug 05;52(9):6213-21
pubmed: 21666235
Int J Ophthalmol. 2017 Sep 18;10(9):1436-1445
pubmed: 28944205
Clin Ophthalmol. 2017 Jun 12;11:1113-1118
pubmed: 28652697